Skip to main content
. 2017 Oct 25;9(1):62–69. doi: 10.1007/s12672-017-0313-6

Fig. 2.

Fig. 2

Duration of progression-free survival with mitotane as a monotherapy or with polychemotherapy ± mitotane in patients with multiple responses or stabilizations. Gray lines refer to mitotane as a monotherapy and black lines to polychemotherapy ± mitotane. Fourteen patients experienced multiple partial responses (patients 1 and 2) or multiple stabilizations (patients 3 to 14)